Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker SKYE
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 14, 2026 | SCHEDULE 13G | SKYE Skye Bioscience, Inc. | Tang Capital Partners IV, Inc | 60,002 | 1.4% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | SKYE Skye Bioscience, Inc. | Tang Capital Partners III, Inc | 60,002 | 1.4% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | SKYE Skye Bioscience, Inc. | Tang Capital Partners International, LP | 83,556 | 1.8% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | SKYE Skye Bioscience, Inc. | Tang Capital Partners, LP | 60,000 | 1.4% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | SKYE Skye Bioscience, Inc. | Kevin Tang | 263,560 | 6.0% | SCHEDULE 13G ↗ |
| Oct 14, 2026 | SCHEDULE 13G | SKYE Skye Bioscience, Inc. | Tang Capital Management, LLC | 263,560 | 6.0% | SCHEDULE 13G ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Scott M. Rocklage | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | John D. Diekman | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Kush Parmar | 1.19M | 25.7% | SCHEDULE 13D/A ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Andrew J. Schwab | 1.22M | 26.1% | SCHEDULE 13D/A ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Co-Investors II, L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Ventures II, L.P. | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Partners II, LLC | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Ventures VII, L.P. | 1.19M | 25.7% | SCHEDULE 13D/A ↗ |
| Sep 24, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Partners VII, LLC | 1.19M | 25.7% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Scott M. Rocklage | 1.47M | 4.1% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | John D. Diekman | 1.47M | 4.1% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Kush Parmar | 9.62M | 25.9% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Andrew J. Schwab | 11.27M | 30.2% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Co-Investors II, L.P. | 55,663 | 0.2% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Ventures II, L.P. | 1.41M | 4.0% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Partners II, LLC | 1.47M | 4.1% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Ventures VII, L.P. | 9.62M | 25.9% | SCHEDULE 13D/A ↗ |
| Aug 18, 2026 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Partners VII, LLC | 9.62M | 25.9% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Scott M. Rocklage | 1.51M | 4.7% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | John D. Diekman | 1.51M | 4.7% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Kush Parmar | 9.87M | 29.2% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | Andrew J. Schwab | 11.54M | 34.0% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Co-Investors II, L.P. | 57,493 | 0.2% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Ventures II, L.P. | 1.46M | 4.5% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Partners II, LLC | 1.51M | 4.7% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Ventures VII, L.P. | 9.87M | 29.2% | SCHEDULE 13D/A ↗ |
| Dec 16, 2025 | SCHEDULE 13D/A (amended) | SKYE Skye Bioscience, Inc. | 5AM Partners VII, LLC | 9.87M | 29.2% | SCHEDULE 13D/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G/A (amended) | SKYE Skye Bioscience, Inc. | Schonfeld Strategic Advisors LLC | 1.12M | 3.6% | SCHEDULE 13G/A ↗ |
| May 15, 2025 | SCHEDULE 13G | SKYE Skye Bioscience, Inc. | Schonfeld Strategic Advisors LLC | 1.62M | 5.2% | SCHEDULE 13G ↗ |
| Apr 10, 2025 | SCHEDULE 13G/A (amended) | SKYE Skye Bioscience, Inc. | Sphera Global Healthcare Management LP. | 1.48M | 4.8% | SCHEDULE 13G/A ↗ |
| Apr 10, 2025 | SCHEDULE 13G/A (amended) | SKYE Skye Bioscience, Inc. | Sphera Global Healthcare GP Ltd. | 1.48M | 4.8% | SCHEDULE 13G/A ↗ |
| Apr 10, 2025 | SCHEDULE 13G/A (amended) | SKYE Skye Bioscience, Inc. | Sphera Funds Management Ltd. | 1.48M | 4.8% | SCHEDULE 13G/A ↗ |
38 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 11:35 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances